FDA
-
-
-
-
-
-
-
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
-
-
-
-
-
-
-
Goldman Sachs Downgrades Incyte (INCY) to Neutral
-
-
-
-
-
-
-
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
-
-
-
-
-
-
-
Incyte (INCY) falls as GSK wins approval for Ojjaara
-
-
-
-
-
-
-
Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
-
-
-
-
-
-
-
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
-
-
-
-
-
-
-
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
-
251,412 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All